Gary E. Duncan, Ph.D.



Gary Duncan, Ph.D.


Phone: (919) 966-8237



B.S., Biology, Georgia State University
Ph.D., Pharmacology, University of Louisville


Research Interests:

Dr. Duncan’s research involves behavioral and neurochemical studies in mouse models of psychosis, with the hope of finding new approaches to treat schizophrenia. Another area of work involves developing science education strategies for a wide range of students, from elementary school kids to Psychiatry residents.

In basic research studies with antipsychotic drugs, Dr. Duncan examines biochemical and behavioral effects of the drugs in animal models. The models are based on manipulation of brain chemistry by drugs and genetic engineering to mimic changes that may occur in schizophrenia. Better understanding of biological abnormalities associated with the models could help define novel and more effective treatment strategies for schizophrenia.


Representative Publications:

1.   Duncan, G.E., Koller, B.H., Moy S.S. Effects of the selective kainate receptor antagonist ACET on altered sensorimotor gating in a genetic model of reduced NMDA receptor function. Brain Research 1443: 98-105, 2012.

2.   Duncan, G.E. Inada, K., Koller, B.H., Moy S.S. Increased sensitivity to kainic acid in a genetic model of NMDA receptor hypofunction. Brain Research 1307: 166-176, 2010.

3.    Duncan, G.E., Inada, K, Farrington, J.S., Koller, B.H., and Moy, S.S. Neural activation deficits in a mouse genetic model of NMDA receptor hypofunction in tests of social aggression and swim stress. Brain Research 1265: 186-1955, 2009.

4.    Moy, S.S., Nadler, J.J., Poe, M.D., Nonneman, R.J., Young, N.B., Koller, B.H. Crawley, J.N., Duncan, G.E., Bodfish, J.W. Development of a Mouse Test for Repetitive, Restricted Behaviors: Relevance to Autism. Behavioral Brain Research 118: 178-194, 2008.

5.    Duncan G.E., Moy, S.S., Lieberman, J.A., Koller, B.H. Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function. Psychopharmacology 184: 190-200, 2006.